Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Smith, I. E.
Biganzoli, L.
Cortes-Funes, H.
Stroyakovskiy, D.
Franke, F. A.
Chlistalla, A.
Pierga, J-Y
Thomssen, C.
Pritchard, K.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp Prato, Tuscany Canc Inst, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] City Clin Oncol Hosp, Moscow, Russia
[5] Hosp Caridade Ijui, Ijui, Brazil
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Inst Curie, Paris, France
[8] Univ Halle Wittenberg, Halle, Germany
[9] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：286S / 286S
页数：1
相关论文
共 50 条
  • [1] MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)
    Pierga, J.
    Pritchard, K. I.
    Cortes-Funes, H.
    Biganzoli, L.
    Thomssen, C.
    Franke, F. A.
    Smith, I. E.
    Bogdanova, N.
    Stroyakovskiy, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Franke, F.
    Kamel, Y. Mostafa
    Pierga, J. Y.
    Pritchard, K. I.
    Stroyakovs, D.
    Thomssen, C.
    Vinholes, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 221
  • [3] Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391
    Cortes-Funes, H.
    Pritchard, K. I.
    Biganzoli, L.
    Thomssen, C.
    Pierga, J.
    Koza, I.
    Kwong, A.
    Kellokumpu-Lehtinen, P.
    Chlistalla, A.
    Smith, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 266
  • [4] Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT
    Pierga, J.
    Pritchard, K. I.
    Thomssen, C.
    Cortes-Funes, H.
    Biganzoli, L.
    Padrik, P.
    Zvirbule, Z.
    Smith, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
    Smith, I. E.
    Pierga, J. -Y.
    Biganzoli, L.
    Cortes-Funes, H.
    Thomssen, C.
    Pivot, X.
    Fabi, A.
    Xu, B.
    Stroyakovskiy, D.
    Franke, F. A.
    Kaufman, B.
    Mainwaring, P.
    Pienkowski, T.
    De Valk, B.
    Kwong, A.
    Gonzalez-Trujillo, J. L.
    Koza, I.
    Petrakova, K.
    Pereira, D.
    Pritchard, K. I.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 595 - 602
  • [6] First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
    Thomssen, C.
    Pierga, J-Y
    Pritchard, K., I
    Biganzoli, L.
    Cortes-Funes, H.
    Petrakova, K.
    Kaufman, B.
    Smith, I. E.
    CANCER RESEARCH, 2009, 69 (24) : 854S - 854S
  • [7] Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Miles, D. W.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 266
  • [8] Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study
    Pivot, X.
    Verma, S.
    Thomssen, C.
    Passos-Coelho, J. L.
    Latini, L.
    Ciruelos, E.
    Silva, M.
    von Moos, R.
    Chang, H.
    Miles, D. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study
    Biganzoli, L.
    Cortes-Funes, H.
    Thomssen, C.
    Pritchard, K. I.
    Pierga, J.
    Kupp, A.
    Borstnar, S.
    Smith, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study
    Dirix, L. Y.
    Romieu, G.
    Provencher, L.
    Grimes, D.
    de Souzo, Viana L.
    Paterson, A.
    Mauriac, L.
    Kirsch, A.
    Pernas, S.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 285S - 285S
12345